{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+A&page=44",
    "query": {
      "intervention": "Period A",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 12649,
    "total_pages": 1265,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+A&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Period+A&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T09:36:52.515Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01450631",
      "title": "The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post-operative Complications",
        "Surgical Site Infection",
        "Surgical Wound Infection"
      ],
      "interventions": [
        {
          "name": "Prevena™ Incision Management System (PIMS)",
          "type": "DEVICE"
        },
        {
          "name": "Standard-of-care Dressing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "KCI USA, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 92,
      "start_date": "2012-02",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01450631"
    },
    {
      "nct_id": "NCT06217302",
      "title": "Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Nephropathies",
        "Kidney Failure, Chronic",
        "Diabetes Mellitus Type 1",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alessandro Doria",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-10-31",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 13,
      "location_summary": "Stanford, California • Aurora, Colorado • Orlando, Florida + 10 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06217302"
    },
    {
      "nct_id": "NCT01892345",
      "title": "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2014-04-11",
      "completion_date": "2018-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892345"
    },
    {
      "nct_id": "NCT02432651",
      "title": "Xanthohumol and Prevention of DNA Damage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "6 mg xanthohumol per day",
          "type": "DRUG"
        },
        {
          "name": "12 mg xanthohumol per day",
          "type": "DRUG"
        },
        {
          "name": "24 mg xanthohumol per day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-03",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2018-11-06",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Corvallis, Oregon",
      "locations": [
        {
          "city": "Corvallis",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432651"
    },
    {
      "nct_id": "NCT03126331",
      "title": "Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2017-08-03",
      "completion_date": "2023-10-24",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126331"
    },
    {
      "nct_id": "NCT01059877",
      "title": "Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dementia"
      ],
      "interventions": [
        {
          "name": "1072nm infrared Photobiomodulation",
          "type": "DEVICE"
        },
        {
          "name": "Photobiomodulation SIMULATED",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Quietmind Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 11,
      "start_date": "2010-01",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Plymouth Meeting, Pennsylvania",
      "locations": [
        {
          "city": "Plymouth Meeting",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059877"
    },
    {
      "nct_id": "NCT02439788",
      "title": "3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "GINAKIT Cells",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-08",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02439788"
    },
    {
      "nct_id": "NCT01763203",
      "title": "The SUCCEED Trial of Secondary Stroke Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke",
        "Secondary Stroke Prevention"
      ],
      "interventions": [
        {
          "name": "Care Management+Community Health Worker",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 487,
      "start_date": "2014-02-13",
      "completion_date": "2019-02-11",
      "has_results": true,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 6,
      "location_summary": "Downey, California • Los Angeles, California • Sylmar, California + 1 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763203"
    },
    {
      "nct_id": "NCT06016842",
      "title": "A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Biliary Cholangitis (PBC)"
      ],
      "interventions": [
        {
          "name": "Elafibranor",
          "type": "DRUG"
        },
        {
          "name": "Matched 80 mg placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2023-08-31",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06016842"
    },
    {
      "nct_id": "NCT03173170",
      "title": "A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "TAK-954",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-05-31",
      "completion_date": "2017-07-24",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-11-08T09:36:52.515Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173170"
    }
  ]
}